로그인|회원가입|고객센터|기업교육 문의
페이지 맨 위로 이동
검색

Global Business

Korea United Pharm signs cancer drug export deals

Dong-A Ilbo | Updated 2026.10.23
At GBPP 2026, signs major anticancer drug supply contracts with pharmaceutical firms in the Philippines and Vietnam
Secures US$ 2.5 million deal with QualiMed in the Philippines
Locks in US$ 770,000 order volume with Dai Nam in Vietnam
Korea United Pharm signs export contract for anticancer drugs with Vietnam. Courtesy of Korea United Pharm
Korea United Pharm Inc. (CEO Kang Duk-Young) accelerated its expansion into the Southeast Asian market by successfully signing anticancer drug supply contracts worth a total of USD 3.27 million (KRW 4.4 billion) with local pharmaceutical companies in the Philippines and Vietnam at Global Bio & Pharma Plaza (GBPP) 2026, held at KINTEX in Goyang, Gyeonggi Province.

GBPP, hosted by the Ministry of Trade, Industry and Energy and co-organized by the Korea Trade-Investment Promotion Agency (KOTRA) and the Korea Pharmaceutical Traders Association (KPTA), is the largest global pharmaceutical business event in Korea. It supports domestic pharmaceutical and biotechnology companies in developing overseas distribution channels and strengthening export capabilities.

On the back of close cooperation with KOTRA, Korea United Pharm has steadily expanded its global network by leveraging various government support programs, including the Export Voucher Program and the Overseas Branch Office Program. At this year’s event, the company secured a dedicated consultation space at the venue from October 21 to 22 and held extensive discussions with leading overseas buyers on new business partnerships and strategies to increase exports.

Back-to-back contracts with key pharmaceutical companies in the Philippines and Vietnam…USD 3.27 million in orders secured

The most significant outcome of these contracts was achieved on the opening day of the event. Korea United Pharm signed separate order contracts with major companies that hold strong influence in the Philippine and Vietnamese pharmaceutical markets.

First, the company concluded a supply contract for multiple anticancer drugs worth a total of USD 2.5 million with Qualimed Pharma Inc., a major pharmaceutical distributor in the Philippines. It then finalized an export contract worth USD 770,000 with Dai Nam Ha Noi JSC, a major pharmaceutical importer in Vietnam, for the anticancer drug “Hydrin Capsule” (ingredient: Hydroxyurea 500 mg). Through these contracts, the company has established a foothold for stable supply of its key anticancer product lineup to major Southeast Asian hub countries.

Korea United Pharm signs export contract for anticancer drugs with the Philippines. Courtesy of Korea United Pharm
Aiming at a USD 7 billion annual mega-market…Capturing explosive pharmaceutical demand

The Philippines and Vietnam, targeted by Korea United Pharm, are key strategic locations in Southeast Asia where pharmaceutical consumption is rapidly increasing, driven by the expansion of medical infrastructure and rising household incomes.

According to an industry analysis report by global market research firm BMI, the Philippine pharmaceutical market is projected to grow sharply from approximately USD 6.1 billion in 2024 to around USD 7.5 billion by 2029. Vietnam’s market is also expected to expand significantly from approximately USD 4.7 billion in 2023 to about USD 6.3 billion by 2029, based on KOTRA analysis data. As both countries are seeing substantial growth in high value-added markets for specialty drugs, including anticancer therapies, expectations for additional orders are high.

Anticancer technology recognized…Diversifying distribution channels across Asia

A Korea United Pharm official stated, “These consecutive export contracts in the Philippines and Vietnam represent a meaningful achievement, proving the excellent quality and price competitiveness of Korea United Pharm’s anticancer product portfolio in the rapidly growing Southeast Asian pharmaceutical and biotechnology markets. Building on this performance as a catalyst, the company plans not only to further diversify its anticancer prescription portfolio in both countries, but also to reinforce its brand presence and market dominance throughout Southeast Asia.”

Kim Sang-jun

AI-translated with ChatGPT. Provided as is; original Korean text prevails.
Popular News

경영·경제 질문은 AI 비서에게,
무엇이든 물어보세요.

Click!